Key result
A higher vagal neuroimmunomodulation index was associated with improved overall survival in patients with advanced pancreatic cancer (RR 0.68; 95% CI 0.51-0.92) and non-small cell lung cancer.
Why the study?
Does a higher vagal neuroimmunomodulation (NIM) index predict improved overall survival in patients with advanced pancreatic or non-small cell lung cancer?
Population
273 Belgian patients, comprising 202 with advanced pancreatic cancer and 71 with non-small cell lung cancer.
Comparison
Higher vagal neuroimmunomodulation index vs Lower NIM index
Design
Cohort
Authors
Loading...
NIM index may aid prognosis in fatal cancers; leaves open whether vagal activity causally influences survival.
Cohort (n=273)
Does a higher vagal neuroimmunomodulation (NIM) index predict improved overall survival in patients with advanced pancreatic or non-small cell lung cancer?
Relative Risk: 0.68 (95% CI 0.51–0.92)
The NIM index, reflecting vagal modulation of inflammation via the RMSSD/CRP ratio, may serve as an independent prognostic biomarker for survival in advanced pancreatic and non-small cell lung cancers.
Gidron et al. (2018) conducted a cohort in Advanced pancreatic cancer and non-small cell lung cancer (n=273). Vagal neuroimmunomodulation (NIM) index vs. Lower NIM index was evaluated on Overall survival (RR 0.68, 95% CI 0.51-0.92). A higher vagal neuroimmunomodulation index was associated with improved overall survival in patients with advanced pancreatic cancer (RR 0.68; 95% CI 0.51-0.92) and non-small cell lung cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: